GV 2021 GP, L.L.C.
GV 2021 GP, L.L.C.'s purchase track record
How the stock did after each of GV 2021 GP, L.L.C.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/1/2025 | PRME | $4.95M | +22.3% | -5.7% | +11.2% |
| 5/3/2023 | GOOG | $19.67M | +21.2% | +20.2% | +3.6% |
| 3/13/2023 | GOOG | $18.99M | +35.7% | +50.3% | +16.4% |
| 11/4/2022 | GOOG | $24.83M | +21.4% | +22.5% | +9.7% |
| 5/24/2022 | GOOG | $456K | +8.3% | -8.1% | +1.6% |
| 5/10/2022 | GOOG | $12.30M | +2.5% | -22.4% | -4.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alphabet's Gemini AI appears in Geely's overseas car exports. Google has integrated its Gemini generative AI model into Geely's overseas car models, allowing the automaker to use AI features in exported vehicles. This expands Alphabet's AI reach beyond its own services and may create new licensing revenue. Analysts also cite a forecast that Alphabet could become larger than Apple by 2027, indicating confidence in its growth. The stock is near its $340 support level, with a neutral RSI and a trailing P/E of 17.4.
Transaction History
| PRME | ▲ Buy | Open Market | 1,500,000 | $5.0M | 8/1/2025 | View on chart |
| GOOG | ▲ Buy | Open Market | 7,286 | $197K | 5/5/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 302,483 | $8.1M | 5/4/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 91,710 | $2.5M | 5/4/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 2,168 | $61K | 5/4/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 287,470 | $8.1M | 5/3/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 22,461 | $650K | 5/3/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 169,156 | $5.1M | 3/14/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 55,051 | $1.7M | 3/14/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 119,798 | $3.4M | 3/13/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 152,251 | $4.4M | 3/13/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 126,938 | $3.8M | 3/13/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 16,013 | $496K | 3/13/2023 | View on chart |
| GOOG | ▲ Buy | Open Market | 128,911 | $4.4M | 11/9/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 42,833 | $1.5M | 11/9/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 10,568 | $381K | 11/9/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 25,159 | $915K | 11/8/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 14,264 | $513K | 11/8/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 65,421 | $2.3M | 11/7/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 100 | $4K | 11/7/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 136,376 | $4.8M | 11/7/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 121,424 | $4.3M | 11/4/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 141,028 | $5.1M | 11/4/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 15,041 | $560K | 11/4/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 13,528 | $456K | 5/24/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 14,860 | $490K | 5/12/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 9,183 | $310K | 5/12/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 76,136 | $2.6M | 5/11/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 82,055 | $2.8M | 5/10/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 77,391 | $2.7M | 5/10/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 80,488 | $2.8M | 5/10/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 15,513 | $567K | 5/10/2022 | View on chart |
| GOOG | ▲ Buy | Open Market | 200 | $7K | 5/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647
Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.